MX2012009186A - Pirrolidina-2-carboxamidas sustituidas. - Google Patents
Pirrolidina-2-carboxamidas sustituidas.Info
- Publication number
- MX2012009186A MX2012009186A MX2012009186A MX2012009186A MX2012009186A MX 2012009186 A MX2012009186 A MX 2012009186A MX 2012009186 A MX2012009186 A MX 2012009186A MX 2012009186 A MX2012009186 A MX 2012009186A MX 2012009186 A MX2012009186 A MX 2012009186A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- carboxamides
- substituted pyrrolidine
- compounds
- pyrrolidine
- Prior art date
Links
- VLJNHYLEOZPXFW-UHFFFAOYSA-N pyrrolidine-2-carboxamide Chemical class NC(=O)C1CCCN1 VLJNHYLEOZPXFW-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula (Ver formula) en donde X, Y, R1, R2, R3, R3, R4, R5, R6 y R7 tienen los significados aquí descritos y los enantiómeros y sales y ésteres farmacéuticamente aceptables de los mismos. Estos compuestos son útiles como agentes anticancerosos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/702,402 US8354444B2 (en) | 2008-09-18 | 2010-02-09 | Substituted pyrrolidine-2-carboxamides |
PCT/EP2011/051619 WO2011098398A1 (en) | 2010-02-09 | 2011-02-04 | Substituted pyrrolidine-2-carboxamides |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012009186A true MX2012009186A (es) | 2012-08-23 |
Family
ID=43608850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012009186A MX2012009186A (es) | 2010-02-09 | 2011-02-04 | Pirrolidina-2-carboxamidas sustituidas. |
Country Status (32)
Country | Link |
---|---|
US (1) | US8354444B2 (es) |
EP (1) | EP2534132B1 (es) |
JP (1) | JP5612710B2 (es) |
KR (1) | KR101461298B1 (es) |
CN (1) | CN102753522B (es) |
AR (2) | AR080143A1 (es) |
AU (1) | AU2011214506C1 (es) |
BR (1) | BR112012019672B1 (es) |
CA (1) | CA2788236C (es) |
CL (1) | CL2012002189A1 (es) |
CR (1) | CR20120410A (es) |
CY (1) | CY1119049T1 (es) |
DK (1) | DK2534132T3 (es) |
EC (1) | ECSP12012083A (es) |
ES (1) | ES2629439T3 (es) |
HK (1) | HK1171452A1 (es) |
HR (1) | HRP20170903T1 (es) |
HU (1) | HUE034816T2 (es) |
LT (1) | LT2534132T (es) |
MX (1) | MX2012009186A (es) |
MY (1) | MY165238A (es) |
NZ (1) | NZ601422A (es) |
PE (1) | PE20121532A1 (es) |
PL (1) | PL2534132T3 (es) |
PT (1) | PT2534132T (es) |
RS (1) | RS56163B1 (es) |
RU (1) | RU2564022C2 (es) |
SG (1) | SG182763A1 (es) |
SI (1) | SI2534132T1 (es) |
TW (1) | TWI401243B (es) |
UA (1) | UA107954C2 (es) |
WO (1) | WO2011098398A1 (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7303676B2 (en) * | 2003-02-13 | 2007-12-04 | Zenon Technology Partnership | Supported biofilm apparatus and process |
GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
JP5099731B1 (ja) | 2009-10-14 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | p53活性を増大する置換ピペリジン及びその使用 |
US8088815B2 (en) * | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
US20120010235A1 (en) * | 2010-07-12 | 2012-01-12 | Xin-Jie Chu | N-substituted pyrrolidines |
US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
WO2012121361A1 (ja) | 2011-03-10 | 2012-09-13 | 第一三共株式会社 | ジスピロピロリジン誘導体 |
WO2013062923A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp. | MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
US9062071B2 (en) | 2011-12-21 | 2015-06-23 | Merck Sharp & Dohme Corp. | Substituted piperidines as HDM2 inhibitors |
US8993614B2 (en) * | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
US20130245089A1 (en) * | 2012-03-19 | 2013-09-19 | Hoffmann-La Roche Inc. | Method for administration |
US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
US20140200255A1 (en) * | 2012-03-19 | 2014-07-17 | Brian Higgins | Method for administration |
RU2014150492A (ru) * | 2012-05-30 | 2016-07-20 | Ф. Хоффманн-Ля Рош Аг | Замещенные пирролидин-2-карбоксамиды |
TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
ES2707305T3 (es) | 2012-12-20 | 2019-04-03 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de HDM2 |
AU2014210103B2 (en) * | 2013-01-22 | 2018-09-06 | F. Hoffmann-La Roche Ag | Pharmaceutical composition with improved bioavailability |
RU2015133939A (ru) * | 2013-02-21 | 2017-03-27 | Ф. Хоффманн-Ля Рош Аг | Асимметрический синтез замещенного пирролидин-2-карбоксамида |
WO2014158638A1 (en) * | 2013-03-13 | 2014-10-02 | Dow Agrosciences Llc | Preparation of certain (substituted phenyl)-triazolyl-(substituted phenyl) molecules, and intermediates and insecticides related thereto |
JP6549107B2 (ja) * | 2013-06-19 | 2019-07-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんの処置のための、ro5503781、カペシタビン及びオキサリプラチンの組み合わせ |
CN105307660A (zh) * | 2013-06-19 | 2016-02-03 | 豪夫迈·罗氏有限公司 | 用于癌症治疗的ro5503781和卡培他滨的组合 |
AU2014301324A1 (en) * | 2013-06-24 | 2015-12-10 | F. Hoffmann-La Roche Ag | Stable intravenous formulation |
RU2016101514A (ru) | 2013-07-03 | 2017-08-08 | Ф. Хоффманн-Ля Рош Аг | ЭКСПРЕССИЯ мРНК ГЕНОВ ДЛЯ ПЕРСОНАЛИЗАЦИИ ПРОТИВООПУХОЛЕВОЙ ТЕРАПИИ ПАЦИЕНТОВ АНТАГОНИСТОМ MDM2 |
SI3077004T1 (sl) | 2013-12-05 | 2020-07-31 | F. Hoffmann-La Roche Ag | Novo kombinirano zdravilo za akutno mieloično levkemijo (AML) |
US9657351B2 (en) | 2013-12-06 | 2017-05-23 | Hoffman-La Roche Inc. | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist |
ES2928706T3 (es) * | 2014-04-15 | 2022-11-22 | Hoffmann La Roche | Formas sólidas de un compuesto farmacéuticamente activo |
ES2712973T3 (es) | 2014-04-17 | 2019-05-17 | Univ Michigan Regents | Inhibidores de MDM2 y métodos terapéuticos que usan los mismos |
JP6162646B2 (ja) * | 2014-05-27 | 2017-07-12 | 信越化学工業株式会社 | 3,5−ジメチルドデカン酸の製造方法 |
CN106716131B (zh) * | 2014-10-10 | 2020-07-24 | 豪夫迈·罗氏有限公司 | Mdm2拮抗剂的癌症疗法的患者个性化方法 |
NZ736450A (en) * | 2015-03-30 | 2022-04-29 | Mission Therapeutics Ltd | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
EP3458101B1 (en) | 2016-05-20 | 2020-12-30 | H. Hoffnabb-La Roche Ag | Protac antibody conjugates and methods of use |
KR102122469B1 (ko) | 2016-11-01 | 2020-06-12 | 주식회사 엘지화학 | 변성 공액디엔계 중합체 및 이의 제조방법 |
WO2018120094A1 (zh) | 2016-12-30 | 2018-07-05 | 泸州东方农化有限公司 | 一种制备2-(亚环己烯基)丙二酸衍生物的方法及其应用 |
GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
EP3651752A1 (en) | 2017-07-11 | 2020-05-20 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
CN108586195A (zh) * | 2017-12-27 | 2018-09-28 | 北京汇康博源医药科技有限公司 | 一种5-羟基-7,7-二甲基-2h-茚酮的制备方法 |
WO2019213106A1 (en) | 2018-04-30 | 2019-11-07 | Teva Pharmaceuticals International Gmbh | Solid state forms of idasanutlin |
CR20220316A (es) | 2019-12-06 | 2022-10-07 | Vertex Pharma | Tetrahidrofuranos sustituidos como moduladores de canales de sodio |
AR126073A1 (es) | 2021-06-04 | 2023-09-06 | Vertex Pharma | N-(hidroxialquil(hetero)aril)tetrahidrofuran carboxamidas como moduladores de canales de sodio |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
CN116459225B (zh) * | 2023-04-26 | 2023-11-10 | 东莞市金美济药业有限公司 | 一种艾拉戈克钠片及其制备工艺 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4732902A (en) | 1986-05-23 | 1988-03-22 | Hoffmann-La Roche Inc. | Pyrroloisoquinolinyl-dimethyloxoalkyl alkonoates and their use as antipsychotic agents |
TW394760B (en) | 1993-09-07 | 2000-06-21 | Hoffmann La Roche | Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same |
EP1019364B1 (en) | 1997-08-28 | 2004-06-09 | Biovitrum Ab | Inhibitors of protein tyrosine phosphatase |
US6482921B1 (en) | 1999-01-28 | 2002-11-19 | Essential Therapeutics, Inc. | Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use |
US6531494B1 (en) | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
US6916833B2 (en) * | 2003-03-13 | 2005-07-12 | Hoffmann-La Roche Inc. | Substituted piperidines |
CN1294120C (zh) * | 2003-10-21 | 2007-01-10 | 山东大学 | 吡咯烷类基质金属蛋白酶抑制剂及其应用 |
US7550487B2 (en) * | 2004-03-26 | 2009-06-23 | Hoffmann-La Roche Inc. | Pyrrolidine-3,4-dicarboxamide derivatives |
EA019566B1 (ru) | 2005-02-22 | 2014-04-30 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Низкомолекулярные ингибиторы mdm2 |
US7759383B2 (en) * | 2005-02-22 | 2010-07-20 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
BRPI0612045A2 (pt) | 2005-06-17 | 2018-07-24 | Astrazeneca Ab | composto, formulação farmacêutica, uso de um composto, método de tratamento de uma condição, e, processo para preparação de um composto |
JP2009542666A (ja) | 2006-06-30 | 2009-12-03 | シェーリング コーポレイション | P53活性を増加させる置換ピペリジンおよびその使用 |
EP2104497B1 (de) | 2006-12-06 | 2015-02-25 | Sanofi | Sulfamidderivate als inhibitoren von tafia |
WO2009004383A2 (en) | 2007-07-03 | 2009-01-08 | Astrazeneca Ab | Aza-bicyclohexane compounds useful as anticoagulants |
JO2704B1 (en) * | 2007-09-21 | 2013-03-03 | جانسين فارماسوتيكا ان في | Interference inhibition factors between MD2 and B53 |
US8134001B2 (en) * | 2007-12-14 | 2012-03-13 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
JP5531011B2 (ja) | 2008-06-06 | 2014-06-25 | サノフイ | TAFIaの阻害剤としての大環状尿素およびスルファミド誘導体 |
CA2727925A1 (en) | 2008-06-23 | 2009-12-30 | Astrazeneca Ab | New heterocyclic carboxamides for use as thrombin inhibitors |
GB0811643D0 (en) * | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
DK2340021T3 (da) * | 2008-09-18 | 2012-12-10 | Hoffmann La Roche | Substituerede pyrrolidin-2-carboxamider |
US8017607B2 (en) | 2009-10-14 | 2011-09-13 | Hoffmann-La Roche Inc. | N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions |
-
2010
- 2010-02-09 US US12/702,402 patent/US8354444B2/en active Active
-
2011
- 2011-02-04 ES ES11702449.7T patent/ES2629439T3/es active Active
- 2011-02-04 CA CA2788236A patent/CA2788236C/en active Active
- 2011-02-04 DK DK11702449.7T patent/DK2534132T3/en active
- 2011-02-04 SG SG2012055752A patent/SG182763A1/en unknown
- 2011-02-04 RS RS20170658A patent/RS56163B1/sr unknown
- 2011-02-04 KR KR1020127023297A patent/KR101461298B1/ko active IP Right Grant
- 2011-02-04 PT PT117024497T patent/PT2534132T/pt unknown
- 2011-02-04 NZ NZ601422A patent/NZ601422A/en unknown
- 2011-02-04 RU RU2012138257/04A patent/RU2564022C2/ru active
- 2011-02-04 CN CN2011800089274A patent/CN102753522B/zh active Active
- 2011-02-04 PE PE2012001184A patent/PE20121532A1/es active IP Right Grant
- 2011-02-04 WO PCT/EP2011/051619 patent/WO2011098398A1/en active Application Filing
- 2011-02-04 BR BR112012019672-3A patent/BR112012019672B1/pt active IP Right Grant
- 2011-02-04 MX MX2012009186A patent/MX2012009186A/es active IP Right Grant
- 2011-02-04 JP JP2012552343A patent/JP5612710B2/ja active Active
- 2011-02-04 EP EP11702449.7A patent/EP2534132B1/en active Active
- 2011-02-04 AU AU2011214506A patent/AU2011214506C1/en active Active
- 2011-02-04 LT LTEP11702449.7T patent/LT2534132T/lt unknown
- 2011-02-04 MY MYPI2012003543A patent/MY165238A/en unknown
- 2011-02-04 SI SI201131222T patent/SI2534132T1/sl unknown
- 2011-02-04 PL PL11702449T patent/PL2534132T3/pl unknown
- 2011-02-04 HU HUE11702449A patent/HUE034816T2/en unknown
- 2011-02-07 AR ARP110100393A patent/AR080143A1/es active IP Right Grant
- 2011-02-08 TW TW100104166A patent/TWI401243B/zh active
- 2011-04-02 UA UAA201210421A patent/UA107954C2/ru unknown
-
2012
- 2012-08-03 EC ECSP12012083 patent/ECSP12012083A/es unknown
- 2012-08-07 CL CL2012002189A patent/CL2012002189A1/es unknown
- 2012-08-07 CR CR20120410A patent/CR20120410A/es unknown
- 2012-11-29 HK HK12112287.3A patent/HK1171452A1/xx unknown
-
2017
- 2017-06-13 HR HRP20170903TT patent/HRP20170903T1/hr unknown
- 2017-06-23 CY CY20171100673T patent/CY1119049T1/el unknown
-
2018
- 2018-12-13 AR ARP180103640A patent/AR114159A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012009186A (es) | Pirrolidina-2-carboxamidas sustituidas. | |
MX2012003982A (es) | Pirrolidinas n-substituidas. | |
MX2014014229A (es) | Pirrolidina-2-carboxamidas sustituidas. | |
MY160424A (en) | Substituted pyrrolidine-2-carboxyamides. | |
MY160596A (en) | Spiroindolinone pyrrolidines | |
TW200801000A (en) | Spiroindolinone derivatives | |
IL205354A0 (en) | Spiroindolinone derivatives | |
MX2011008176A (es) | Derivados de 3,3'-espiroindolinona como agentes anticancerigenos. | |
IL193620A0 (en) | Spiroindolinone derivatives | |
TW200612958A (en) | Substituted imidazole derivatives | |
PH12014501542B1 (en) | Substituted pyrrolidine -2- carboxamides | |
IL205506A0 (en) | Spiroindolinone derivatives as anticancer agents | |
MX2013003019A (es) | Compuestos de azabenzotiazol, composiciones y metodos de uso. | |
MX2016006336A (es) | Compuestos pirazolopirimidina. | |
TW200800951A (en) | Substituted imidazole compounds as KSP inhibitors | |
CR20200286A (es) | DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294) | |
TN2009000287A1 (en) | Cyclized derivatives as eg-5inhibitors | |
WO2011088027A8 (en) | Compounds and methods | |
WO2011143772A9 (en) | Inhibitors of hiv replication | |
MX2011007886A (es) | Derivado de espiroindolinona piridina. | |
WO2014062838A3 (en) | Pkm2 modulators and methods for their use | |
MX2013009386A (es) | Nuevos compuestos de azaespirodecanona. | |
MX2013002694A (es) | Derivados de tetrahidroquinolina usados como activadores de proteina cinasa activada por monofosfato de adenosina. | |
MX346980B (es) | Nuevos compuestos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona y octahidropiridinona. | |
MX2013002656A (es) | Nuevo proceso. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |